Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Detection of Hepatocellular Carcinoma in Cirrhotic Patients Using Circulating Methylated SEPT9 Markers

  • By

  • Abderrahim Oussalah

  • Maël Silva Rodriguez

  • Guillaume Conroy

  • Mouni Bensenane

  • Hélène Rousseau

  • Ahmet Ayav

  • Jean-Louis Guéant

  • Houda Camara

  • Cédric Baumann

  • Valérie Laurent

  • Jean-Pierre Bronowicki

  • SEPT9_CROSS Study Group

  • Vincent Haghnejad

  • Claire Geist

  • Raphaelle Riffault

  • Abdelbasset Nani

  • Julien Levy

  • Jonas Callet

  • September 1, 2026

Share

  • 1

    Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality, with 866,000 new cases and 759,000 deaths globally in 2022.

  • 2

    Current surveillance for HCC in cirrhotic patients includes abdominal ultrasonography and α-fetoprotein (AFP) measurement every six months.

  • 3

    Methylated SEPT9 is an epigenetic biomarker that may improve HCC detection among cirrhotic patients compared to AFP alone.

  • 4

    This study was a prospective, blinded, cross-sectional investigation conducted in France, comparing methylated SEPT9 and AFP for HCC diagnosis.

  • 5

    The study aimed to assess whether methylated SEPT9 could enhance existing surveillance strategies for early-stage HCC detection.

Original Source(s)

Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis

  • by Abderrahim Oussalah, Maël Silva Rodriguez, Guillaume Conroy, Mouni Bensenane, Hélène Rousseau, Ahmet Ayav, Jean-Louis Guéant, Houda Camara, Cédric Baumann, Valérie Laurent, Jean-Pierre Bronowicki, SEPT9_CROSS Study Group, Vincent Haghnejad, Claire Geist, Raphaelle Riffault, Abdelbasset Nani, Julien Levy, Jonas Callet

  • September 1, 2026

Related Content

Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

Clinician Counseling and Weight Loss Attempts Among Survivors of Obesity-Associated Cancers

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα